Tivic Health Systems

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Hayward, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tivic Health Systems reports revenue growth and strategic advancements in Q1 2024

Tivic Health Systems showcased revenue growth and strategic initiatives in their Q1 2024 earnings call, emphasizing progress in bioelectronic medicine and clinical studies.
While facing challenges in managing a net loss and optimizing sales dynamics, the company's strengths lie in fiscal responsibility, product innovation, and market expansion.
Opportunities abound for Tivic Health to capitalize on their VNS program success, ClearUp product momentum, and strategic funding for future growth and value creation.
By balancing financial discipline with innovation, Tivic Health aims to navigate challenges, leverage strengths, and seize opportunities for sustainable growth and market leadership.

Tivic Health Systems advances VNS technology amidst financial challenges

Tivic Health Systems is making strides in VNS technology development and clinical research, despite facing financial and compliance challenges. With a strong patent portfolio and a focus on innovation, the company is well-positioned to capitalize on emerging opportunities in the medical device market.

Tivic Health Systems navigates challenges, eyes growth in VNS market

Tivic Health Systems faces financial challenges but shows resilience through strategic focus on profitability, innovation, and operational efficiency.
The company's progress in the VNS program and market assessment efforts position it well for future growth and market expansion opportunities.
With a new CFO onboard and a proactive approach to addressing product challenges, Tivic Health is poised to navigate challenges and capitalize on growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Fremont, CA.

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I'd like to take this opportunity to recap some of the important developments this year and share some of our expectations for 2025. Improvements in Commercial Business: We launched ClearUP 2.0, resulting in improved c.

CEO Letter to Shareholders Issued by Tivic Health

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st.

Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Operator Welcome to Tivic Health Systems' Third Quarter 2024 Financial Results and Operational Update Conference Call. This call has been pre-recorded and questions you have submitted in advance will be answered following the prepared remarks.

Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomi.

Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes these validations are an important step toward securing the foundation for an international market position. Newly validated patents in Great Britain, Germany and France: European Patent E.

Tivic Health Validates European Patents in Great Britain, Germany, and France

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be.

Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic Medicine, will identify device parameters, including frequency and duration of treatment, that optimally influ.

First Subject Enrolled in Tivic Health's Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst's presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company's advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation. “This yea.

Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation (“ncVNS”) approach. This clinical research collaboration with Feinstein is designed to advance the development of Tivic Health's ncVNS.

Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght (“FSI”), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation (“ncVNS”). Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in.

Tivic Health Accelerates VNS Commercial Strategy Development

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions.

Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Kimberly Bambach - Interim Chief Financial Officer Blake Gurfein - Chief Scientific Officer Operator Welcome to the Tivic Health Systems' Second Quarter 2024 Financial Results and Shareholder Update Conference Call. All participants will be in listen-only mode.

Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS"). “This quarter is the start of a potentially transformational period for Tivic. We announced the results of our successful Phase 1 trial of a new approach to non-invasive vagus nerve st.

Tivic Reports Second Quarter 2024 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a.

Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

LOS ANGELES--(BUSINESS WIRE)-- #ASMGlobal--ASM Global — the world's No. 1 development and full-service venue company — has named longtime executive Ralph Marchetta to regional vice president of live entertainment as the world's largest portfolio accelerates its live-entertainment product growth for the industry's largest venue portfolio. Besides booking Desert Diamond Arena — in the midst of an ambitious, significant renovation being spearheaded with ASM Global investment / oversight — and State Farm Stadiu.

ASM Global Continues Its Live Programming Growth Naming Industry Veteran Ralph Marchetta as Regional Vice President of Live Entertainment

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the Virtual Annual General Meeting of Shareholders will be held on Friday, August 9, 2024 at 10:00 a.m., Pacific Time. The Company has adopted a virtual format for our Annual Meeting to provide a healthy, consistent, and convenient experience for all stockholders regardless of location.       WHEN: Friday, Augu.

Tivic Announces 2024 Annual Meeting of Stockholders

Tivic Health Systems (NASDAQ: TIVC ) stock is on the rise Monday as the company's shares have been volatile the last few days of trading. Initially, shares of TIVC stock were pushed higher by a patent update.

Tivic Health Systems (TIVC) Stock Pops Another 39%

Tivic Health Systems (NASDAQ: TIVC ) stock is rising higher on Thursday after the bioelectronic medicine company updated its intellectual property portfolio. According to Tivic Health Systems, it has received two new patents that better protect its intellectual properties.

Why Is Tivic Health Systems (TIVC) Stock Up 44% Today?

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO): US Patent 12,011,592 and European Patent EP3615133, both titled “Adaptive Trigger For a Microcurrent Stimulation Device”, protect device and methods that the company uses to identi.

Tivic Health Expands Intellectual Property Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a strategic advisor to the company since April 2023, and brings over 30-years of experience as a seasoned capital markets professional with extensive analytical and management experience. Ms. Valauri has a prove.

Tivic Health: Christina Valauri Appointed to Board of Directors

Nortech Systems

SANTA CLARA, Calif.--(BUSINESS WIRE)--ServiceNow debuts as a Leader in P&C Claims Management Systems report by independent research firm.

ServiceNow debuts as a Leader in P&C Claims Management Systems report by independent research firm

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”). The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in speci.

Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Ernst – Chief Executive Officer Kimberly Bambach – Interim Chief Financial Officer Conference Call Participants Operator Welcome to the Tivic Health Systems' First Quarter 2024 Financial Results and Shareholder Update Conference Call. All participants will be in listen-only mode.

Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events. "Q1 2024 and the weeks thereafter represent a critical juncture in Tivic's advancement in the bioelectronics field. We increased gross profit and reduced operating loss year-over-year by stabilizing our cost of goods, improving our technolo.

Tivic Reports First Quarter 2024 Financial Results and Subsequent Events

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 464810 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/.

News for Tivic Health Systems Stock (TIVC)